NEW YORK (Reuters Health)—Tabalumab, a monoclonal antibody to B-cell activating factor, was modestly better than placebo in relieving symptoms of systemic lupus erythematosus (SLE), according to results from the ILLUMINATE-2 trial. “Lupus is a complicated disease that does not behave the same way in all patients who share the clinical symptoms,” Dr. Joan T. Merrill…
Naive B Cells Activate & Expand During Lupus Flares
New research published in May indicates a possible connection between B cells and the occurrence of systemic lupus erythematosus symptoms.
Is B a Key to Autoimmune Therapy?: B Cell–targeted Therapies in Autoimmune Disease
A perspective on B cell–targeted therapies in autoimmune disease